Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 3/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258053 | 1.00 | USP2 (0.59) | USP2LPAR5HTTSPHK1CYP1A2 | |
| SCHEMBL11565852 | 0.98 | USP2 (0.56) | USP2LPAR5HTTSPHK1CYP1A2 | |
| Methylamine SCHEMBL28907084 | 0.97 | HTT (0.58) | USP2LPAR5HTTSPHK1CYP1A2 | |
| SCHEMBL13299410 | 0.88 | USP2 (0.54) | USP2LPAR5HTTSPHK1CYP1A2 | |
| SCHEMBL11565849 | 0.86 | USP2 (0.58) | USP2LPAR5HTTSPHK1CYP1A2 | |
| SCHEMBL258038 | 0.84 | RECQL (0.59) | USP2LPAR5HTTSPHK1CYP1A2 | |
| SCHEMBL258049 | 0.84 | RECQL (0.59) | USP2LPAR5HTTSPHK1CYP1A2 | |
| SCHEMBL258062 | 0.84 | LPAR5 (0.41) | USP2LPAR5HTTSPHK1CYP1A2 | |
| SCHEMBL9117095 | 0.84 | USP2 (0.80) | USP2LPAR5HTTSPHK1CYP1A2 | |
| SCHEMBL8527626 | 0.84 | USP2 (0.80) | USP2LPAR5HTTSPHK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968607-B2 | Cosmetics 1-isostearylglycerol-3-Sulfate Sodium Salt, used for constriction of keratinocytes; aging resistance | KOA CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| EP-1325737-B1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORP (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | KAO CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1325737-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | Kao Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | CUTA, DSG1, OGA | USP2 2585/4885LPAR5 115/4885HTT 4782/4885 |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | DSG1, CUTA, OGA | USP2 2626/4885LPAR5 265/4885HTT 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.